AIM: To investigate the efficacy of @entity9820 (TM)-a for treatment of disseminated @entity1003 ( @entity10090 ) in the field of gastrointestinal surgery. METHODS: Thirty-six peri-operative @entity10090 @entity1 in the field of gastrointestinal surgery who were treated with TM-a were retrospectively investigated. The relationships between @entity1 demographics and the efficacy of TM-a were examined. Analysis of survival at 28 d was also performed on some parameters by means of the Kaplan-Meier method. Relationships between the initiation of TM-a and @entity1 demographics were also evaluated. RESULTS: @entity733 formation or @entity2259 was the most frequent cause of @entity10090 (33%), followed by digestive tract perforation (31%). Twenty-six @entity1 developed @entity10090 after surgery, frequently within 1 wk (81%). TM-a was most often administered within 1 d of the @entity10090 diagnosis (72%) and was continued for more than 3 d (64%). Although @entity548 tendency was observed in 7 @entity1 (19%), a hemostatic procedure was not needed. @entity10090 scores, @entity1850 ( @entity1850 ) scores, quick-sequential organ failure assessment (qSOFA) scores, platelet counts, and prothrombin time ratios significantly improved after 1 wk (P < 0.05, for all). The overall survival rate at 28 d was 71%. The duration of TM-a administration (>=  4 , <=  6) and improvements in @entity10090 ( @entity10090 , @entity1850 and qSOFA) at 1 wk were significantly better prognostic factors for 28-d survival (P < 0.05, for all). TM-a was administered significantly earlier to @entity1 with severe clinical symptoms, such as high qSOFA scores, @entity295 , @entity1457 or high lactate values (P < 0.05, for all). CONCLUSION: Early administration of TM-a and improvements in each parameter were essential for treatment of @entity10090 . The diagnosis of @entity1 with mild symptoms requires further study.

Early @entity9820 -a administration outcome for acute disseminated XXXX in gastrointestinal surgery.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity295 :: ('MESH:D018805', 'Disease') :: ['sepsis'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity1457 :: ('MESH:D012769', 'Disease') :: ['shock'] @entity10090 :: ('MESH:D018886', 'Disease') :: ['DIC-associated scores', 'DIC'] @entity1003 :: ('MESH:D001778', 'Disease') :: ['intravascular coagulopathy'] @entity9820 :: ('7056', 'Gene') :: ['thrombomodulin'] @entity733 :: ('MESH:D000038', 'Disease') :: ['Abscess'] @entity1850 :: ('MESH:D018746', 'Disease') :: ['systemic inflammatory response syndrome', 'SIRS'] @entity2259 :: ('MESH:D016470', 'Disease') :: ['bacteremia']
@entity1003 :: (MESH:D001778,Disease) :: ['intravascular coagulopathy']
